Abstract: Acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS) are characterized by rapid-onset respiratory failure after a variety of direct and indirect insults to the parenchyma or vasculature of the lungs. Abundant research has led to improvements in supportive care, but mortality from ALI/ARDS remains substantial. Surprisingly, little research has been done on ALI/ARDS prevention and patients at risk are often studied late into the course of the illness, after admission to intensive care unit. Early detection of atrisk patients is crucial for implementing preventive and therapeutic strategies early in the course. The mechanisms of ALI/ARDS offer an array of possible targets for prevention. Epidemiologic studies suggest a protective role of early treatment of shock and infection, avoidance of tidal hyperventilation, and minimizing plasma transfusion from alloimmunized donors. While systemic steroid administration has a limited role, promising novel pharmacoprevention strategies include antiplatelet agents, systemic and inhaled anticoagulants, inhaled steroids, and systemic administration of antioxidants and HMG-CoA reductase inhibitors. Here, we review recent advances in prevention of ALI/ARDS.
A cute lung injury (ALI) and the acute respiratory distress syndrome (ARDS) complicate critical illness in a large number of patients and have a poor prognosis. The incidence of ALI/ARDS has been variably reported to be 50,000 to 190,000 cases per year in the United States. 1 The incidence of ALI in 2 recent studies has been estimated to be 22 in 86 cases per 100,000 persons per year, with 40% to 43% of these patients presenting with ARDS. [2] [3] [4] The efficacy of ALI/ARDS treatment is limited once the condition is fully established. Enormous basic and clinical research efforts have led to improvements in supportive treatment, but surprisingly little has been done to prevent this devastating syndrome. 5, 6 
DEFINITION AND CLINICAL PATHOGENESIS OF ARDS
The American-European Consensus Committee (AECC) in 1994 defined clinical ALI as respiratory failure of acute onset with PaO 2 /FiO 2 ratio r300 mm Hg and ARDS as <200 mm Hg [regardless of the level of positive end expiratory pressure (PEEP)], bilateral infiltrates on frontal chest radiograph, and pulmonary capillary wedge pressure <18 mm Hg (if measured) or no evidence of left atrial hypertension, as the principal explanation for pulmonary edema. The AECC definition of ALI/ARDS is widely used and simple to apply, but also has serious deficiencies in discrimination. There is often not a good correlation between these broad clinical definitions and diffuse alveolar damage, which is widely considered to be a major characteristic histologic feature of ALI/ARDS. 7 The AECC definitions also do not take into consideration variables such as the mode of ventilation and the level of PEEP, which can significantly influence oxygenation. The AECC definitions of ALI/ARDS are thus frequently supplemented by lung injury or critical care scores such as the Murray score and Acute Physiology and Chronic Health Evaluation score in adults, the Pediatric Risk of Mortality score, 8 Pediatric Index of Mortality score, and Oxygenation Index 9 in children. An alternative definition of ARDS by a recent Delphi consensus panel of senior investigators includes PEEP restrictions in defining hypoxemia, radiographic criteria for air space disease in 2 or more quadrants, and requires either quantitative compliance abnormalities or the presence of a predisposing condition. 10 Although the Delphi definition is more specific than the AECC criteria, it has been reported to be less sensitive. 10 ALI/ARDS can arise in patients of all ages from direct (pneumonia, aspiration, near drowning, smoke inhalation, lung contusion) or indirect (sepsis, shock, severe trauma, fat embolism, transfusion, acute pancreatitis, drug intoxication) insults that induce pulmonary inflammation, damage the alveolocapillary membrane, and lead to noncardiogenic pulmonary edema with severe acute respiratory failure (Fig. 1) . 12 The pathophysiological consequences of ALI/ARDS are related to altered pulmonary capillary permeability and alveolar diffusion capacity and also increased intrapulmonary shunt. ALI/ARDS can be divided into 2 histopathologic phases. The exudative phase (1 to 3 d) is characterized by diffuse alveolar damage with widespread type I pneumocytes necrosis, diffuse microvascular injury, and influx of inflammatory cells and proteinaceous fluid into the interstitium and alveolar space. The fibroproliferative phase (3 to 7 d) is a process of lung repair manifested as type II pneumocytes hyperplasia and proliferation of fibroblasts. 13 Multiple clinical risk factors have been identified to be associated with ARDS. Prospective studies done in Seattle and Denver for identification of clinical predisposition or risk factors for ARDS in the 1980s found a 26% overall incidence in intensive care unit (ICU) patients with predisposing conditions. The incidence was higher with sepsis (38% to 43%), gastric aspiration (30%), multiple trauma (25%), and transfusions (25% to 40%).
14, 15 Ferguson et al 16 studied all hospitalized patients with clinical risk factors identified in the above studies and found a lower overall incidence of ALI (6.5%) and ARDS (4%). In the recent prospective multicenter study, shock (17%), aspiration (16.5%), and high-risk surgery (16%) showed the highest risk for developing ARDS. 17 In 18, 21 Although the exact pathophysiological mechanism is not known, both animal and human studies support glutathione depletion and hence alterations in surfactant synthesis, apoptosis, and alveolar permeability to be plausible mechanistic explanation of this association. 22 However, the role of timing and intensity of alcohol exposure, altered mental state, and aspiration or coexposures such as nutritional deficiencies and blood product transfusions have yet to be defined. The key to prevent ARDS would be 2-fold, one would be to identify why only a fraction of patients with risk factors go on to develop ARDS and the second would be instituting measures to reduce modifiable risk factors.
EARLY IDENTIFICATION OF PATIENTS WITH OR AT RISK OF ARDS
The first prerequisite for developing effective prevention strategies is the identification of high-risk patients before the progression to a full blown syndrome. A recent epidemiologic study observed that patients who require high oxygen supplementation in the emergency room (O 2 >2 L/min) are more likely to progress into ALI/ARDS and respiratory failure. The investigators defined a clinical diagnosis of early ALI in patients who present with bilateral opacities on chest radiograph not exclusively due to left atrial hypertension and initially require oxygen supplementation of >2 L/min (73% sensitive and 79% specific for progression to ALI/ARDS with respiratory failure) at the time of hospital admission.
Identifying the patients at risk before the development of ALI provides the best chance for effective prevention. Recently, we developed the Lung Injury Prediction score (LIPS) that was subsequently prospectively validated in a multicenter study. Predisposing conditions at the time of or before hospital admission, which were identified as risk factors for ALI/ARDS in at least 2 previous studies were entered into a multiple logistic regression model with ALI/ARDS as the dependent variable. LIPS points were determined based on parameter estimates from the logistic regression model taking into consideration results from previous studies. A LIPS score of 4 and above can identify patients at high risk of development of ALI/ARDS and has a good discrimination (Area under ROC curve 0.80). 17, 23 The LIPS model uses clinical information readily available at the time of hospital admission and may potentially be used to alert providers to identify high-risk patients to avoid specific "second-hit" hospital exposures (Table 1) .
IDENTIFICATION OF OPTIMAL TIMING FOR APPLYING POTENTIAL ARDS PREVENTION STRATEGIES
Previous studies have exclusively focused on patients admitted to the ICU. 4, 19, 22, [24] [25] [26] [27] The inferences from these studies with regard to ALI pathogenesis and potential preventive strategies are limited because: (1) The diagnosis of ALI/ARDS is made in the ICU, but the biological process begins much earlier. 24, 28 In fact, the need for mechanical ventilation to treat ALI/ARDS is frequently the very reason for ICU admission. Meaningful approach to ALI/ARDS prevention therefore ought to be based on identifying patients at risk and relevant exposure earlier than what is currently done (at the time of hospital, rather than ICU admission). (2) A significant number of patients with predisposing conditions are never admitted to the ICU. 16 As those patients have not been included into ICU-based studies, there is limited understanding why these patients do not develop ALI/ARDS. (3) Clinical studies were almost exclusively performed at single referral institutions with limited generalizability. 29 Our data from a recent population-based cohort study 30 confirmed that ARDS is rarely present on admission and without a prior contact with the health care system, but rather develops after admission and under our watch. The time gap between hospital admission and the onset of ARDS highlights the need to identify patients at risk early in the course of their illness by developing accurate prediction models. Once these patients are identified, our efforts should be directed towards creating and testing potential preventive strategies during this limited time window.
PREVENTION STRATEGIES FOR ARDS
ARDS prevention is a novel topic and firm evidencebased recommendations are lacking. Intriguing data from a recent population-based cohort study suggests that improvements in health care delivery and avoidance of second-hit exposures can limit or prevent ARDS in patients at risk. 30 These include but are not limited to early recognition and treatment of 
Early Recognition and Treatment of Shock and Infection
Shock and infection could induce ALI/ARDS through indirect and direct injury to the lung. Delayed treatment of shock and infection has been shown to be associated with the development of ALI/ARDS. 20 Thus, promptly identifying and treating shock in the emergency department, operating room or the hospital ward is important for prevention of ARDS. Early diagnosis and treatment of respiratory infection based on results of gram staining significantly reduced the incidence of ARDS without an increase in the use of antibiotics. 31 
Protective Mechanical Ventilation
The association with the potentially injurious initial ventilator settings, in particular large tidal volumes and high airway pressures, suggests that ARDS in mechanically ventilated patients is in part a preventable complication. 32 Ventilation with small tidal volumes is recommended in patients with established ALI/ARDS. 33 The association between the initial tidal volume and the development of ALI/ARDS in patients intubated for reasons other than ALI/ ARDS suggests that ventilator-associated lung injury may be an important cause of this syndrome. While the topic is still controversial, it is difficult to justify the use of higher than normal (6 to 8 mL/kg predicted body weight) respiratory tidal volumes even in patients without ALI/ARDS at the onset of mechanical ventilation. 34, 35 Height and sex should be considered when setting up the ventilator, as they are better predictors of lung size than actual weight of the patient. 32 
Transfusion and Fluid
Transfusion is associated with an increased risk of the development of ALI/ARDS in critically ill patients. The risk is higher with transfusions of plasma-rich blood products, fresh frozen plasma, and platelets, than with red blood cells. 24, 28, 36, 37 Indeed, a quality improvement intervention aimed at decreasing ventilator tidal volume and liberal transfusion not only decreased harmful exposures, but was also associated with a reduced incidence of ALI/ARDS in mechanically ventilated patients without ALI at the outset. 35 While conservative fluid management is important after ALI/ARDS development, the role of fluid amount and composition in prevention of ALI/ ARDS is controversial and critically dependent on timing of fluid infusion. 38 In patients with septic shock complicated by ARDS, early liberal followed by later conservative fluid management were associated with improved outcome. 38 
Prevention of Aspiration and Ventilatorassociated Pneumonia
Aspiration could cause direct injury to the alveolarcapillary membrane mediated by inhalation of the acid, chemical, particulate, and microbiological composition of the aspirate. The 30 degrees head-up position could reduce gastric aspiration in ventilated patients in the ICU. Rapid sequence intubation is essential to prevent aspiration during emergency surgery and trauma. The initial management of witnessed aspiration involves positioning the patient head-down, maintenance of cricoid pressure if possible, clearing the airway of debris with suctioning, and securing the airway with an endotracheal tube. Bronchoscopy may be used to remove suspected foreign body or larger aspirated particles. 39 VAP is not only a common complication of ALI/ARDS but also an important cause of direct lung injury. The so-called "ventilator bundle" aimed at prevention of VAP and related complications in mechanically ventilated patients contains 5 components: elevation of head of the bed to 30 to 45 degrees, daily "sedation vacation," daily assessment of readiness to extubate, peptic ulcer disease prophylaxis, and deep venous thrombosis prophylaxis. Daily spontaneous awakening and breathing trials are associated with earlier liberation from mechanical ventilation and VAP reduction. 40 Other methods to reduce VAP, such as oral care and hygiene, selective digestive decontamination, chlorhexidine in the posterior pharynx and specialized endotracheal tubes (continuous aspiration of subglottic secretions, silver coated), should be considered for inclusion in a revised "ventilator bundle" more specifically aimed at VAP prevention. Adapted with permission from Gajic et al. 17 
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Pharmacoprevention Targets
The experimental evidence from animal models indicates that ARDS can be prevented by blocking pathways involved in oxidative stress, inflammatory and procoagulant response to tissue injury or infection.
High-dose systemic steroid administration has been ineffective in prevention of ARDS and was associated with worse outcome in patients with septic shock. 42 In contrast, inhaled steroids may represent an attractive novel option that should be considered for testing as a prophylactic treatment in patients at risk of ARDS. There is accumulating evidence to support a preliminary clinical trial of inhaled corticosteroids in patients at high risk of ARDS and with early and/or late ARDS. 43 The use of aerosolized unfractionated heparin and N-acetylcysteine attenuates lung injury and the progression of ARDS in ventilated adult patients with ALI after smoke inhalation. 44, 45 Other anti-inflammatory agents are being proposed and are under current clinical investigation (eg, indomethacin, acetylcysteine, a-1-proteinase inhibitor, antitumor necrosis factor, interleukin 1 receptor antagonist, platelet-activating factor antagonists). 46 Lipid lowering drugs such as statins are known to have anti-inflammatory properties. In vitro studies with statins have shown them to protect against vascular leak and inflammation of ALI. 47 Further trials are underway. Treatment with statins was associated with improved survival after chronic obstructive pulmonary disease exacerbation, whereas inhaled corticosteroids appeared to increase the survival benefit associated with statin use. 48, 49 Use of prehospitalization antiplatelet therapy may reduce the incidence of ALI. 50 Although antioxidant treatments such as N-acetyl cysteine and ketoconazole were ineffective in treatment of mechanically ventilated patients with established ARDS, they may have a role as a prevention strategy in patients at risk. [51] [52] [53] Pulmonary edema fluid clearance from the alveolar space can be augmented by both inhaled and systemic b-2-adrenoceptor agonists (b-2 agonists). In addition, b-2 agonists may reduce lung vascular permeability, increase the secretion of surfactant, and have anti-inflammatory effects. In view of these potentially beneficial effects, b-2 agonist should be evaluated for prevention of lung injury in humans, particularly because they are already in wide clinical use and do not seem to have serious adverse effects in critically ill patients. 54 Potential therapeutic targets in early ALI also include modulation of inflammatory or procoagulant response, optimization of fluid balance, pulmonary vasodilatation, and minimizing oxygen toxicity. 55 
SUMMARY
ALI/ARDS is a very severe and common syndrome in critically ill patients with high mortality and morbidity. The mechanisms of ALI/ARDS development are still not fully understood. To our knowledge they involve direct or indirect injury to alveolar-capillary membrane secondary to chemical, biological, and mechanical causes and are perpetuated by oxidative stress, uncontrolled proinflammatory and procoagulant response. The treatment of ALI/ARDS is limited when the syndrome is fully developed. Preliminary studies suggest the possibility and feasibility of early identification of patients at risk with a goal of prevention of the development and progression of ALI/ARDS. A new shift from a "supportive treatment" to a "comprehensive prevention strategy" of ALI/ARDS is needed to improve the outcome of a critically ill patient.
